

# Histogenics signs merger agreement with Ocugen

Client News

April 8, 2019

Gunderson Dettmer client Histogenics, a developer of restorative cell therapies for pain management, has entered into a **definitive merger agreement** with Ocugen, a privately held pharmaceutical company targeting rare and underserved eye diseases, to create a publicly-traded clinical-stage biopharmaceutical company. The merged company will operate under the name Ocugen.

The Gunderson Dettmer deal team included Marc Dupre, Albert Vanderlaan, Keith Scherer, Daniel Riley and Samantha Gross.

## Related People



Marc F. Dupre

PARTNER

P +1 617 648 9220





Keith J. Scherer

PARTNER

P +1 617 648 9231

## Featured Insights

### CLIENT NEWS

Gunderson Dettmer Advises Antler and Peak XV in Airalo's \$220 Million Unicorn Financing

### CLIENT NEWS

EDBI Invests in \$11M Series A+ Financing of Augmentus

### CLIENT NEWS

Propel Venture Partners Announces \$100M Fund V

### CLIENT NEWS

Boldstart Ventures Announces \$250M Fund VII

### CLIENT NEWS

Avenue Growth Partners Closes \$7M Series A Financing of Temelio

### INSIGHTS

Client Insight: One, Big, Beautiful Bill Enactment: Impacts To Qualified Small Business Stock

### CLIENT NEWS

Further Ventures Leads \$3.2M Series Seed of BridgePort

## INSIGHTS

### Recent Fund Formations Represented by Gunderson Dettmer\*

## CLIENT NEWS

### Savvy Wealth Raises \$72M Series B Led By Industry Ventures

## FIRM NEWS

### LMG Life Sciences Shortlists Gunderson Dettmer and Boston Associate Joel Diamond for 2025 Life Sciences Americas Awards

## CLIENT NEWS

### Mexico-Based Fintech Klar Announces \$190M Series C and \$800M Valuation

## CLIENT NEWS

### Certify Raises \$40M Series B Led by Transformation Capital